Comparative Pharmacology
Head-to-head clinical analysis: CENTRAX versus TEMAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENTRAX versus TEMAZ.
CENTRAX vs TEMAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
Temazepam, a benzodiazepine, enhances the effect of gamma-aminobutyric acid (GABA) at the GABA-A receptor, increasing chloride ion conductance and causing neuronal hyperpolarization, leading to anxiolytic, sedative, and hypnotic effects.
10-30 mg orally, 3-4 times daily.
Temazepam 15-30 mg orally at bedtime, up to 60 mg if needed.
None Documented
None Documented
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Clinical Note
moderateTemazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Temazepam is combined with Fluticasone propionate."
Clinical Note
moderateTemazepam + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Temazepam."
Clinical Note
moderateTemazepam + Haloperidol
"The risk or severity of adverse effects can be increased when Temazepam is combined with Haloperidol."
Clinical Note
moderateTemazepam + Sulfisoxazole
Terminal elimination half-life: 1.5–2 hours; in severe renal impairment (CrCl <30 mL/min), half-life may extend to 4–6 hours, requiring dose adjustment.
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Renal: ~80% as unchanged drug and metabolites; biliary/fecal: ~20%.
Category C
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Sulfisoxazole can be decreased when combined with Temazepam."